English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Serum S100B is related to illness duration and clinical symptoms in schizophrenia: A meta-regression analysis

Schümberg, K., Polyakova, M., Steiner, J., & Schroeter, M. L. (2016). Serum S100B is related to illness duration and clinical symptoms in schizophrenia: A meta-regression analysis. Frontiers in Cellular Neuroscience, 10: 46. doi:10.3389/fncel.2016.00046.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-002B-1FD8-2 Version Permalink: http://hdl.handle.net/21.11116/0000-0003-1100-9
Genre: Journal Article

Files

show Files
hide Files
:
Schümberg_2016.pdf (Publisher version), 2MB
Name:
Schümberg_2016.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Schümberg, Katharina1, Author              
Polyakova, Maryna1, Author              
Steiner, Johann2, Author
Schroeter, Matthias L.1, 3, 4, 5, Author              
Affiliations:
1Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634549              
2Department of Psychiatry, Otto von Guericke University Magdeburg, Germany, ou_persistent22              
3Clinic for Cognitive Neurology, University of Leipzig, Germany, ou_persistent22              
4Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany, ou_persistent22              
5Consortium for Frontotemporal Lobar Degeneration, Ulm, Germany, ou_persistent22              

Content

show
hide
Free keywords: Glia; Meta-analysis; S100B; Schizophrenia; Serum marker
 Abstract: S100B has been linked to glial pathology in several psychiatric disorders. Previous studies found higher S100B serum levels in patients with schizophrenia compared to healthy controls, and a number of covariates influencing the size of this effect have been proposed in the literature. Here, we conducted a meta-analysis and meta-regression analysis on alterations of serum S100B in schizophrenia in comparison with healthy control subjects. The meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to guarantee a high quality and reproducibility. With strict inclusion criteria 19 original studies could be included in the quantitative meta-analysis, comprising a total of 766 patients and 607 healthy control subjects. The meta-analysis confirmed higher values of the glial serum marker S100B in schizophrenia if compared with control subjects. Meta-regression analyses revealed significant effects of illness duration and clinical symptomatology, in particular the total score of the Positive and Negative Syndrome Scale (PANSS), on serum S100B levels in schizophrenia. In sum, results confirm glial pathology in schizophrenia that is modulated by illness duration and related to clinical symptomatology. Further studies are needed to investigate mechanisms and mediating factors related to these findings.

Details

show
hide
Language(s): eng - English
 Dates: 2015-12-022016-02-092016-02-25
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.3389/fncel.2016.00046
PMID: 26941608
PMC: PMC4766293
Other: eCollection 2016
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Frontiers in Cellular Neuroscience
  Other : Front. Cell. Neurosci.
  Abbreviation : FNCEL
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Frontiers Research Foundation
Pages: - Volume / Issue: 10 Sequence Number: 46 Start / End Page: - Identifier: Other: 1662-5102
CoNE: https://pure.mpg.de/cone/journals/resource/1662-5102